Eagle seeks FDA OK for ready-to-use bivalirudin
This article was originally published in Scrip
Eagle Pharmaceuticals is seeking the FDA's approval under to market a ready-to-use (RTU) intravenous version of bivalirudin, which is the same active ingredient in The Medicine Company's anticoagulant Angiomax, which had US sales of $600m last year.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.